Linezolid Dose-Ranging Study

The purpose of this study is to evaluate the mycobactericidal activity, safety, tolerability, and pharmacokinetics of 5 doses of linezolid

Background:

The purpose of this study is to evaluate the mycobactericidal activity, safety, tolerability, and pharmacokinetics of 5 doses of linezolid: 300 mg once per day, 300 mg twice per day, 600 mg once per day, 600 mg twice per day and 1200 mg once per day administered orally for 14 consecutive days in adult subjects with newly diagnosed drug‐sensitive, smear‐positive pulmonary tuberculosis.

Additional Resources

A Phase 2 Trial to Evaluate the Efficacy and Safety of Linezolid in Tuberculosis Patients

Phase 2 (Early)

Trial Components

Solo Compounds